Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Clear Secure Inc (YOU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Clear Secure Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Clear Secure Inc trades at $55.25 (market cap $5.56B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.2× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.09% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | YOU | |
|---|---|---|
Market Cap | $39.89B | $5.56B |
Sector | Health | Technology |
52-Week High | $491.22 | $62.36 |
52-Week Low | $278.09 | $28.38 |
Enterprise Value | $38.15B | $4.88B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Clear Secure (YOU) trades at $55.22, down 1.6% on the day, with a bullish technical signal from moving averages and strong fundamental growth. Recent earnings beat expectations in Q1 2026, and the company expanded services with AWS integration and new airport launches. Revenue reached $900.78M in 2025, with net income of $109.17M and robust cash flow from operations of $372.45M.
Outlook remains positive due to earnings momentum and strategic expansions, but risks include high valuation multiples and competitive pressures. Analyst consensus is mixed with a $56.67 price target, suggesting moderate upside potential from current levels amid balanced sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
